Compare Sanofi SA (SNY) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Wolfspeed Inc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Wolfspeed Inc trades at $31.94 (market cap $1.53B). The key difference: Sanofi SA is far larger — about 68.5× Wolfspeed Inc's market cap, and Sanofi SA pays a 5.5% dividend while Wolfspeed Inc pays none. Which is the better fit depends on your goals.
| SNY | WOLF | |
|---|---|---|
Market Cap | $104.83B | $1.53B |
Sector | Health | Technology |
52-Week High | $52.34 | $73.68 |
52-Week Low | $41.33 | $1.19 |
Enterprise Value | $121.32B | $2.19B |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
WOLF trades at $29.38, down 1.71% with bearish technical signals despite oversold RSI readings. The company shows negative profitability metrics with -79.83% net income margin and -14.54% ROE, though recent earnings beat expectations in two of three quarters. Strategic shifts toward data centers and defense markets alongside patent litigation activity create mixed sentiment.
Outlook remains challenging due to persistent losses and competitive pressures, though analyst consensus leans slightly bullish with 31.58% buy ratings. Key risks include execution on margin improvement and market share battles in the competitive semiconductor space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
